Norway, Nov. 6 -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has signed a strategic master supply agreement with Telix Pharmaceuticals, a global radiopharmaceutical company headquartered in Australia.The five-year agreement is for Thor Medical to supply Telix with thorium-228, which Telix will use as precursor for production of lead-212 for its next-generation therapeutics pipeline. The thorium-228 will be supplied from Thor Medical's AlphaOne site, the company's first commercial-scale plant for radioisotopes currently under construction with planned production start in Q3 2026. Telix is a commercial-stage and rapidly growing radiopharmaceutical company focusing on advance...